Dr. Majid Y. Moridani
My Social Links

Dr. Majid Y. Moridani

National Jewish Health, USA

Highest Degree
PostDoc. in Clinical Chemistry from University of Toronto, Canada

Share this Profile


Dr. Majid Moridani is currently the Director of Special Chemistry and Toxicology Section of the Clinical Laboratory at Froedtert Hospital, a 650 bed hospital, and Professor of Chemistry and Toxicology, Department of Pathology at Medical College of Wisconsin, Milwaukee, WI, USA.His prior work experience includes: theDirector of Clinical Pharmacokinetics Laboratory and Associate Professor at NJH, Denver, Colorado, and Assistant Professor of Pharmaceutical Sciences at the Department of Pharmaceutical Sciences, Texas Tech School of Pharmacy, Amarillo, Texas. He has over 20 years of combined experience in Pharmaceutical and Medicinal Chemistry, Drug Metabolism and Toxicology,Clinical Chemistry and Clinical Toxicology.After his PhD studies,he completed aPostdoctoral Fellowship in Clinical Chemistry at Department of Laboratory Medicine, School of Medicine, University of Toronto, Canada, and a Postdoctoral Fellowship in Drug Metabolism and Biochemical Toxicology atFaculty of Pharmacy, University of Toronto, Canada. He has earned his PhD inPharmaceutical/Medicinal Chemistry, from Kings College London, University of London, London, UK in 1996 and Doctor of Pharmacy degree (PharmD) from Faculty of Pharmacy, Tehran Medical Sciences University,Tehran, Iran in 1993.He is board certified in Clinical Chemistry (DABCC) and a Fellow of National Academy of Clinical Biochemistry (FACB).During his career he received a number of Awards, Scholarships, Honors, and Certificates from various institutes. He holds the position of the President of Asian Council of Science Editors. He is also serving on 3 journals as an editorial board member,the vice-chair of Translational Research and Individualized Medicine at International Pharmaceutical Federation (FIP)and also acted as a referee to more than 20 scientific journals. He is involved with a number of scientific societies such as FIP, AAPS, AACC, and AACR.He received a number of grants for his research, and taught various pharmacy and PhD postgraduate level courses at Texas Tech School of Pharmacy, and supervised several PhD students and postdoctoral fellows in his career. He is also the Director of Clinical Chemistry Rotation in Pathology Residency Program at Department of Pathology, Medical College of Wisconsin. He has published over 65papers including research articles, book chapters, and review articles, and gave over 100 poster presentations and 150 invited talks in academia and industry at National and International Meetings, including Workshops, Symposiaand Round Tables. He is continuously interested in learning through research, teaching, service, and clinical laboratory practice.

Area of Interest:

Pharmacology and Toxicology
Biochemical Toxicology
Targeted Therapies
Clinical Biochemistry
Oxidative Stress

Research Publications in Numbers


Selected Publications

  1. Moridani, M., 2011. The role of P450 genetic variations in drug and prodrug design. PGx Highlights, 3: 11-16.
  2. Vad, N.M., P.K. Kandala, S.K. Srivastava and M.Y. Moridani, 2010. Structure-toxicity relationship of phenolic analogs as anti-melanoma agents: An enzyme directed prodrug approach. Chem. Biol. Interact., 183: 462-471.
    Direct Link  |  
  3. Thomas, C. and M.Y. Moridani, 2010. Interindividual variations in the efficacy and toxicity of vaccines. Toxicology, 278: 204-210.
    CrossRef  |  
  4. Moridani, M., 2010. Pharmacogenetics of the Renin-Angiotensin-Aldosterone system. PGx Highlights, 2: 6-8.
  5. Moridani, M., 2010. CYP2C19 genotyping for clopidogrel dosing. CAP Today, 24: 14-16.
  6. Kudugunti, S.K., N.M. Vad, A.J. Whiteside, B.U. Naik, M.A. Yusuf, K.S. Srivenugopal adn M.Y. Moridani, 2010. Biochemical mechanism of Caffeic Acid Phenylethyl Ester (CAPE) selective toxicity towards melanoma cell lines. Chem. Biol. Interact., 188: 1-14.
    CrossRef  |  
  7. Brouse, S.D., J.C. Fullerton and M.Y. Moridani, 2010. Reporting and interpretation of CYP2C19 genotyping for clopidogrel dosing. Curr. Pharmac. Personalized Med., 8: 268-272.
    CrossRef  |  
  8. Vad, N.M., S.K. Kudugunti, D. Graber, N. Bailey, K. Srivenugopal and M.Y. Moridani, 2009. Efficacy of acetaminophen in skin B16-F0 melanoma tumor bearing C57BL/6 mice. Int. J. Oncol., 35: 193-204.
    CrossRef  |  
  9. Vad, N.M., G. Yount, D. Moore, J. Weidanz and M.Y. Moridani, 2009. Biochemical mechanism of acetaminophen (APAP) induced toxicity in melanoma cell lines. J. Pharm. Sci., 98: 1409-1425.
    CrossRef  |  
  10. Moridani, M.Y., A.H. Maitland-van der Zee, H. Sasaki, R. McKinnon, L. Fleckenstein and Vinod P. Shah, 2009. AAPS-FIP summary workshop report: Pharmacogenetics in individualized medicine: Methods, regulatory and clinical applications. AAPS J., 11: 214-216.
    CrossRef  |  
  11. Moridani, M., 2009. Technological advances in genomics research. PGx Highlights, 1: 7-9.
  12. Moridani, M., 2009. Response and toxicity variations to vaccines. PGx Highlights, 1: 5-7.
  13. Moridani, M., 2009. Pharmacogenomics testing: Required: Recommended or for information only. PGx Highlights, 1: 6-7.
    Direct Link  |  
  14. Harirforoosh, S., L. Fleckenstein, P. Mahajan, O.I. Aruoma, Y. Huang and M. Moridani, 2009. The importance of including topics related to pharmacogenetics, pharmacogenomics and medical genetics in the pharmacy curriculum. Am. J. Pharmac. Educ., 73: 2-3.
    PubMed  |  
  15. Vad, N.M., G. Yount and M.Y. Moridani, 2008. Biochemical mechanism of acetylsalicylic acid (Aspirin) selective toxicity toward melanoma cell lines. Melanoma Res., 18: 386-399.
    CrossRef  |  
  16. Moridani, M., 2007. Asynchronous video streaming vs. Synchronous videoconferencing for teaching a pharmacogenetic pharmacotherapy course. J. Am. Pharmac. Educ., 71: 1-10.
  17. Moridani, M., 2005. The significance of pharmacogenomics in pharmacy education and practice. J. Am. Pharmac. Educ., 69: 249-250.
  18. Moridani, M., 2004. Pharmacogenomics of Phase I and Phase II drug metabolizing enzymes. CSCC News Lett., 46: 1-3.
  19. Moridani, M., 2004. A SNPpet of background on pharmacogenomics, College of American Pathologists. CAP Today, 18: 60-63.
  20. Moridani, M.Y., S. Khan, T. Chan, S. Teng, K. Beard and P.J. O`Brien, 2001. Cytochrome P450 2E1 metabolically activates propargyl alcohol: Propiolaldehyde-induced hepatocyte cytotoxicity. Chem. Biol. Interact., 130-132: 931-942.
    CrossRef  |  
  21. Galati, G., M.Y. Moridani, T.S. Chan and P.J. O'Brien, 2001. Peroxidative metabolism of apigenin and naringenin versus luteolin and quercetin: Glutathione oxidation and conjugation. Free Radical Biol. Med., 30: 370-382.
    CrossRef  |  Direct Link  |  
  22. Galati, G., S. Teng, M.Y. Moridani, T.S. Chan and P.J. O'Brien, 2000. Cancer chemoprevention and apoptosis mechanisms induced by dietary polyphenolics. Drug Metab. Drug Interact., 17: 311-349.
    PubMed  |  Direct Link  |